Indian pharma and healthcare companies are entering a mixed March quarter. Hospital networks expect steady growth, supported by demand across segments. But generic drugmakers are wrestling with lost Revlimid sales and pricing pressures that weigh on performance. Analysts see pockets of strength: Lupin and Divi’s look set to do well, while Sun Pharma and Torrent show resilience. Apollo Hospitals projects strong overall traction.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
